Stibbe advises ABN AMRO, Deutsche Bank and Morgan Stanley (as joint global coordinators) and the other underwriters on the IPO of ABN AMRO.

Credit Suisse Group AG successfully completed its right offering by issuing 260,983,898 new registered shares generating gross proceeds of CHF 4.7 billion. Credit Suisse acted as Global Coordinator (no firm underwriting). The banking syndicate was led by Citigroup, HSBC Bank plc and Société Générale Corporate & Investment Banking that acted as Joint Lead Managers and Joint Bookrunners.

Advising the Agence des participations de l'Etat (APE), special agency of the Government of France, in connection with the sale by the French State of 11 million of shares of SAFRAN under an accelerated booked building procedure.

Members

* Alexandra Ménard
* Cédric Chanas
* Delphine Vidalenc
* Julien Meillereux
* Laurent Halimi
* Thierry Brocas

Norton Rose Fulbright has advised Lekoil Limited (Lekoil), the AIM-listed oil and gas exploration and development company with a focus on Nigeria and West Africa, in relation to the acquisition of, Ashbert Oil and Gas Limited, the licencee of OPL 325, (located to the south of OPL 310 in the Dahomey Basin) offshore Nigeria, for an initial consideration of US$16.08 million, with additional payments totalling US$24.12 million due at developmental milestones (the OPL 325 acquisition).

EDAG Engineering Group AG, Arbon, Switzerland, has placed 8,750,000 new bearer shares as an initial public offering. The shares of EDAG Engineering AG were listed in the Prime Standard of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) as of 2 December 2015.

Bär & Karrer acted as legal adviser to Deutsche Bank Aktiengesellschaft and Morgan Stanley & Co. International plc on Swiss law aspects. The team included Michael Trippel, Thomas Reutter and Till Spillmann (Capital Markets and Corporate) as well as Daniel Lehmann and Andreas Steffen (Tax).

Allen & Overy has advised Baosteel Group Corporation (Baosteel Group) as keepwell provider and Baosteel Hong Kong Investment Company Limited as issuer on the issue of USD500 million three-year zero-coupon bonds exchangeable into H-shares of China Construction Bank Corporation held by Baosteel Group.
 

Züblin Immobilien Holding AG successfully placed 1’433’387’664 new registered shares in the capital increase at the offer price of CHF 0.05 per offered share. 1’323’868’992 new registered shares corresponding to 92.36% of total shares offered were subscribed by investors exercising pre-emptive rights during the rights exercise period while the remaining 109’518’672 new registered shares were placed in the share offering and purchased by Lamesa Holding S.A.

Travers Smith corporate finance partner Philip Cheveley and corporate finance associate Mark Anderson have advised Zeus Capital Limited (as nominated adviser and broker) to New Broom Limited (to be re-registered as a public limited liability company and to be renamed Purplebricks Group plc) (“Purplebricks”), on its £240.3 million IPO.  The IPO involved the conditional placing of £58 million of existing and new ordinary shares.

Norton Rose Fulbright is acting for leading UK online estate agency Purplebricks on its £240 million AIM lPO.

Purplebricks, which launched in April 2014, is the first online estate agent to list in the UK to list on AIM.

Backed by a number of well-known investors, Purplebricks has conditionally raised £58m from selling shares to institutional investors. The shares are expected to start trading on AIM on December 17, 2015. The IPO will raise £25m for the company while some directors and investors will cash in shares worth £33m.

On December 2, 2015, Santhera Pharmaceuticals Holding AG (SIX: SANN) (Santhera) successfully completed a private placement of 590,000 new shares via an accelerated book building process and raised gross proceeds of CHF 54.8 million. The shares, which represent a 10.4% increase in Santhera's issued share capital, were sold at a price of CHF 93.00 per share. Santhera is a Swiss specialty pharmaceutical company focused on the development and commercialization of products for the treatment of orphan mitochondrial and neuromuscular diseases.